AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Mobix Labs, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) â€� Form 4 insider transaction filed 07/11/2025

Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.

  • Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
  • Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
  • Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.

The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.

Disc Medicine, Inc. (IRON) � Comunicazione Form 4 insider del 11/07/2025

Il CEO e Direttore John D. Quisel ha segnalato l'esercizio di un'opzione e due vendite sul mercato aperto eseguite il 09/07/2025 nell'ambito di un piano di trading Rule 10b5-1 adottato il 13/02/2025.

  • Esercizio opzione (Codice M): 34.800 azioni esercitate a 9,86 $ ciascuna, derivanti da un premio opzione del 1° settembre 2021 che si matura in 48 rate mensili uguali.
  • Vendite (Codice S): Tutte le 34.800 azioni esercitate sono state vendute lo stesso giorno in due tranche: 31.207 azioni a un prezzo medio ponderato di 55,2312 $ (range 55,00-55,99 $) e 3.593 azioni a un prezzo medio ponderato di 56,1995 $ (range 56,00-56,33 $).
  • Posizione netta azionaria: La proprietà effettiva è temporaneamente salita a 196.628 azioni dopo l'esercizio, per poi scendere a 161.828 azioni dopo le vendite, senza variazioni nette rispetto alla posizione precedente alla transazione.

La comunicazione indica una gestione ordinaria della liquidità da parte del CEO; non sono coinvolti flussi di cassa aziendali. Poiché le operazioni erano pianificate in anticipo e il livello complessivo di proprietà è invariato, l'impatto sul mercato dovrebbe essere limitato.

Disc Medicine, Inc. (IRON) � Transacción insider Formulario 4 presentada el 11/07/2025

El Director Ejecutivo y Director John D. Quisel reportó el ejercicio de una opción y dos ventas en mercado abierto realizadas el 09/07/2025 bajo un plan de trading Rule 10b5-1 adoptado el 13/02/2025.

  • Ejercicio de opción (Código M): 34,800 acciones ejercidas a $9.86 por acción, provenientes de una concesión de opción del 1 de septiembre de 2021 que se consolida en 48 cuotas mensuales iguales.
  • Ventas (Código S): La totalidad de las 34,800 acciones ejercidas se vendieron el mismo día en dos tramos: 31,207 acciones a un precio promedio ponderado de $55.2312 (rango $55.00-$55.99) y 3,593 acciones a un precio promedio ponderado de $56.1995 (rango $56.00-$56.33).
  • Posición neta de acciones: La propiedad beneficiaria aumentó brevemente a 196,628 acciones tras el ejercicio, pero descendió a 161,828 acciones tras las ventas, resultando en ningún cambio neto respecto a la participación previa a la transacción.

La presentación indica una gestión rutinaria de liquidez por parte del CEO; no se afectan los flujos de caja de la compañía. Dado que las transacciones fueron planificadas con antelación y el nivel general de propiedad permanece sin cambios, el impacto en el mercado probablemente sea limitado.

Disc Medicine, Inc. (IRON) â€� 2025ë…� 7ì›� 11ì� 제출ë� Form 4 ë‚´ë¶€ìž� 거래 ë³´ê³ 

최고경ì˜ìž�(CEO) ê²� ì´ì‚¬ì� John D. Quiselì€ 2025ë…� 7ì›� 9ì¼ì— 2025ë…� 2ì›� 13ì� 채íƒë� Rule 10b5-1 거래 계íšì—� ë”°ë¼ ì˜µì…˜ 행사 1ê±´ê³¼ 시장 ë‚� 공개 ë§¤ë„ 2ê±´ì„ ë³´ê³ í–ˆìŠµë‹ˆë‹¤.

  • 옵션 행사 (코드 M): 34,800주를 주당 $9.86ì—� 행사했으ë©�, ì´ëŠ” 2021ë…� 9ì›� 1ì� ë¶€ì—¬ëœ ì˜µì…˜ìœ¼ë¡œ 48개월ì—� ê±¸ì³ ë§¤ì›” ë™ì¼í•� 비율ë¡� 권리 ì·¨ë“ì� ì´ë£¨ì–´ì§‘니다.
  • ë§¤ë„ (코드 S): 행사í•� 34,800ì£� 전량ì� ê°™ì€ ë‚� ë‘� 차례ì—� ê±¸ì³ ë§¤ë„했으ë©�, 31,207주는 가중í‰ê·� $55.2312 (범위 $55.00-$55.99), 3,593주는 가중í‰ê·� $56.1995 (범위 $56.00-$56.33)ì—� 매ë„ë˜ì—ˆìŠµë‹ˆë‹�.
  • 순주ì‹� 보유ëŸ�: 행사 ì§í›„ ìœ ìµ ì†Œìœ ê¶Œì€ ìž ì‹œ 196,628주로 ì¦ê°€í–ˆìœ¼ë‚� ë§¤ë„ í›� 다시 161,828주로 ê°ì†Œí•˜ì—¬ 거래 ì � 지분과 비êµí•� 순변ë� ì—†ìŒì� 나타냅니ë‹�.

ì´ë²ˆ ë³´ê³ ëŠ� CEOì� ì¼ìƒì ì¸ 유ë™ì„� 관리임ì� 나타내며, 회사 현금 í름ì—는 ì˜í–¥ì� 없습니다. 거래가 사전 계íšë� 것ì´ê³� ì „ì²´ 소유 ì§€ë¶„ì´ ë³€í•˜ì§€ 않아 시장ì—� 미치ëŠ� ì˜í–¥ì€ 제한ì ì¼ 것으ë¡� 보입니다.

Disc Medicine, Inc. (IRON) � Déclaration Formulaire 4 d’initié déposée le 11/07/2025

Le PDG et administrateur John D. Quisel a déclaré l’exercice d’une option et deux ventes sur le marché libre réalisées le 09/07/2025 dans le cadre d’un plan de trading Rule 10b5-1 adopté le 13/02/2025.

  • Exercice d’option (Code M) : 34 800 actions exercées à 9,86 $ par action, issues d’une attribution d’option du 1er septembre 2021 acquise en 48 versements mensuels égaux.
  • Ventes (Code S) : L’intégralité des 34 800 actions exercées a été vendue le même jour en deux tranches : 31 207 actions à un prix moyen pondéré de 55,2312 $ (fourchette 55,00-55,99 $) et 3 593 actions à un prix moyen pondéré de 56,1995 $ (fourchette 56,00-56,33 $).
  • Position nette en actions : La propriété bénéficiaire a brièvement augmenté à 196 628 actions après l’exercice, mais est retombée à 161 828 actions après les ventes, ce qui entraîne aucun changement net par rapport à la participation avant la transaction.

Le dépôt indique une gestion courante de la liquidité par le PDG ; aucun flux de trésorerie de la société n’est affecté. Étant donné que les transactions étaient planifiées à l’avance et que le niveau global de propriété reste inchangé, l’impact sur le marché devrait être limité.

Disc Medicine, Inc. (IRON) � Form 4 Insider-Transaktion eingereicht am 11.07.2025

Der Geschäftsführer und Direktor John D. Quisel meldete am 09.07.2025 die Ausübung einer Option sowie zwei Verkäufe am offenen Markt im Rahmen eines am 13.02.2025 angenommenen Rule 10b5-1 Handelsplans.

  • Optionsausübung (Code M): 34.800 Aktien wurden zu je 9,86 $ ausgeübt, basierend auf einer Optionszuteilung vom 1. September 2021, die in 48 gleichen monatlichen Raten vestet.
  • Verkäufe (Code S): Die gesamten 34.800 ausgeübten Aktien wurden am selben Tag in zwei Tranchen verkauft: 31.207 Aktien zu einem gewichteten Durchschnittspreis von 55,2312 $ (Spanne 55,00-55,99 $) und 3.593 Aktien zu einem gewichteten Durchschnittspreis von 56,1995 $ (Spanne 56,00-56,33 $).
  • Netto-Aktienposition: Der wirtschaftliche Besitz stieg kurzzeitig auf 196.628 Aktien nach der Ausübung, fiel jedoch nach den Verkäufen auf 161.828 Aktien zurück, was zu keiner Nettoveränderung gegenüber dem Bestand vor der Transaktion führt.

Die Meldung deutet auf eine routinemäßige Liquiditätsverwaltung des CEOs hin; es sind keine Auswirkungen auf die Unternehmensliquidität zu verzeichnen. Da die Transaktionen vorab geplant waren und das Gesamtbesitzniveau unverändert bleibt, ist die Marktauswirkung wahrscheinlich begrenzt.

Positive
  • None.
Negative
  • CEO monetized 34,800 shares at ~$55â€�56, which some investors may interpret as reduced confidence despite the neutral net ownership position.

Insights

TL;DR: CEO exercised options then sold all 34,800 shares; ownership unchanged, routine 10b5-1 activity, limited signal.

The Form 4 shows John D. Quisel converting low-priced options ($9.86) into common stock and immediately liquidating the shares around $55-$56, capturing a sizable personal gain. Importantly, his final holding of 161,828 shares matches the pre-exercise level, so there is no dilution and no directional change in insider ownership. Because the trades were executed under a 10b5-1 plan adopted months earlier, they are less likely to reflect new information about Disc Medicine’s prospects. From an investor-sentiment perspective, the appearance of insider sales can be viewed cautiously, but the neutral net position and pre-planning largely offset this concern.

Disc Medicine, Inc. (IRON) � Comunicazione Form 4 insider del 11/07/2025

Il CEO e Direttore John D. Quisel ha segnalato l'esercizio di un'opzione e due vendite sul mercato aperto eseguite il 09/07/2025 nell'ambito di un piano di trading Rule 10b5-1 adottato il 13/02/2025.

  • Esercizio opzione (Codice M): 34.800 azioni esercitate a 9,86 $ ciascuna, derivanti da un premio opzione del 1° settembre 2021 che si matura in 48 rate mensili uguali.
  • Vendite (Codice S): Tutte le 34.800 azioni esercitate sono state vendute lo stesso giorno in due tranche: 31.207 azioni a un prezzo medio ponderato di 55,2312 $ (range 55,00-55,99 $) e 3.593 azioni a un prezzo medio ponderato di 56,1995 $ (range 56,00-56,33 $).
  • Posizione netta azionaria: La proprietà effettiva è temporaneamente salita a 196.628 azioni dopo l'esercizio, per poi scendere a 161.828 azioni dopo le vendite, senza variazioni nette rispetto alla posizione precedente alla transazione.

La comunicazione indica una gestione ordinaria della liquidità da parte del CEO; non sono coinvolti flussi di cassa aziendali. Poiché le operazioni erano pianificate in anticipo e il livello complessivo di proprietà è invariato, l'impatto sul mercato dovrebbe essere limitato.

Disc Medicine, Inc. (IRON) � Transacción insider Formulario 4 presentada el 11/07/2025

El Director Ejecutivo y Director John D. Quisel reportó el ejercicio de una opción y dos ventas en mercado abierto realizadas el 09/07/2025 bajo un plan de trading Rule 10b5-1 adoptado el 13/02/2025.

  • Ejercicio de opción (Código M): 34,800 acciones ejercidas a $9.86 por acción, provenientes de una concesión de opción del 1 de septiembre de 2021 que se consolida en 48 cuotas mensuales iguales.
  • Ventas (Código S): La totalidad de las 34,800 acciones ejercidas se vendieron el mismo día en dos tramos: 31,207 acciones a un precio promedio ponderado de $55.2312 (rango $55.00-$55.99) y 3,593 acciones a un precio promedio ponderado de $56.1995 (rango $56.00-$56.33).
  • Posición neta de acciones: La propiedad beneficiaria aumentó brevemente a 196,628 acciones tras el ejercicio, pero descendió a 161,828 acciones tras las ventas, resultando en ningún cambio neto respecto a la participación previa a la transacción.

La presentación indica una gestión rutinaria de liquidez por parte del CEO; no se afectan los flujos de caja de la compañía. Dado que las transacciones fueron planificadas con antelación y el nivel general de propiedad permanece sin cambios, el impacto en el mercado probablemente sea limitado.

Disc Medicine, Inc. (IRON) â€� 2025ë…� 7ì›� 11ì� 제출ë� Form 4 ë‚´ë¶€ìž� 거래 ë³´ê³ 

최고경ì˜ìž�(CEO) ê²� ì´ì‚¬ì� John D. Quiselì€ 2025ë…� 7ì›� 9ì¼ì— 2025ë…� 2ì›� 13ì� 채íƒë� Rule 10b5-1 거래 계íšì—� ë”°ë¼ ì˜µì…˜ 행사 1ê±´ê³¼ 시장 ë‚� 공개 ë§¤ë„ 2ê±´ì„ ë³´ê³ í–ˆìŠµë‹ˆë‹¤.

  • 옵션 행사 (코드 M): 34,800주를 주당 $9.86ì—� 행사했으ë©�, ì´ëŠ” 2021ë…� 9ì›� 1ì� ë¶€ì—¬ëœ ì˜µì…˜ìœ¼ë¡œ 48개월ì—� ê±¸ì³ ë§¤ì›” ë™ì¼í•� 비율ë¡� 권리 ì·¨ë“ì� ì´ë£¨ì–´ì§‘니다.
  • ë§¤ë„ (코드 S): 행사í•� 34,800ì£� 전량ì� ê°™ì€ ë‚� ë‘� 차례ì—� ê±¸ì³ ë§¤ë„했으ë©�, 31,207주는 가중í‰ê·� $55.2312 (범위 $55.00-$55.99), 3,593주는 가중í‰ê·� $56.1995 (범위 $56.00-$56.33)ì—� 매ë„ë˜ì—ˆìŠµë‹ˆë‹�.
  • 순주ì‹� 보유ëŸ�: 행사 ì§í›„ ìœ ìµ ì†Œìœ ê¶Œì€ ìž ì‹œ 196,628주로 ì¦ê°€í–ˆìœ¼ë‚� ë§¤ë„ í›� 다시 161,828주로 ê°ì†Œí•˜ì—¬ 거래 ì � 지분과 비êµí•� 순변ë� ì—†ìŒì� 나타냅니ë‹�.

ì´ë²ˆ ë³´ê³ ëŠ� CEOì� ì¼ìƒì ì¸ 유ë™ì„� 관리임ì� 나타내며, 회사 현금 í름ì—는 ì˜í–¥ì� 없습니다. 거래가 사전 계íšë� 것ì´ê³� ì „ì²´ 소유 ì§€ë¶„ì´ ë³€í•˜ì§€ 않아 시장ì—� 미치ëŠ� ì˜í–¥ì€ 제한ì ì¼ 것으ë¡� 보입니다.

Disc Medicine, Inc. (IRON) � Déclaration Formulaire 4 d’initié déposée le 11/07/2025

Le PDG et administrateur John D. Quisel a déclaré l’exercice d’une option et deux ventes sur le marché libre réalisées le 09/07/2025 dans le cadre d’un plan de trading Rule 10b5-1 adopté le 13/02/2025.

  • Exercice d’option (Code M) : 34 800 actions exercées à 9,86 $ par action, issues d’une attribution d’option du 1er septembre 2021 acquise en 48 versements mensuels égaux.
  • Ventes (Code S) : L’intégralité des 34 800 actions exercées a été vendue le même jour en deux tranches : 31 207 actions à un prix moyen pondéré de 55,2312 $ (fourchette 55,00-55,99 $) et 3 593 actions à un prix moyen pondéré de 56,1995 $ (fourchette 56,00-56,33 $).
  • Position nette en actions : La propriété bénéficiaire a brièvement augmenté à 196 628 actions après l’exercice, mais est retombée à 161 828 actions après les ventes, ce qui entraîne aucun changement net par rapport à la participation avant la transaction.

Le dépôt indique une gestion courante de la liquidité par le PDG ; aucun flux de trésorerie de la société n’est affecté. Étant donné que les transactions étaient planifiées à l’avance et que le niveau global de propriété reste inchangé, l’impact sur le marché devrait être limité.

Disc Medicine, Inc. (IRON) � Form 4 Insider-Transaktion eingereicht am 11.07.2025

Der Geschäftsführer und Direktor John D. Quisel meldete am 09.07.2025 die Ausübung einer Option sowie zwei Verkäufe am offenen Markt im Rahmen eines am 13.02.2025 angenommenen Rule 10b5-1 Handelsplans.

  • Optionsausübung (Code M): 34.800 Aktien wurden zu je 9,86 $ ausgeübt, basierend auf einer Optionszuteilung vom 1. September 2021, die in 48 gleichen monatlichen Raten vestet.
  • Verkäufe (Code S): Die gesamten 34.800 ausgeübten Aktien wurden am selben Tag in zwei Tranchen verkauft: 31.207 Aktien zu einem gewichteten Durchschnittspreis von 55,2312 $ (Spanne 55,00-55,99 $) und 3.593 Aktien zu einem gewichteten Durchschnittspreis von 56,1995 $ (Spanne 56,00-56,33 $).
  • Netto-Aktienposition: Der wirtschaftliche Besitz stieg kurzzeitig auf 196.628 Aktien nach der Ausübung, fiel jedoch nach den Verkäufen auf 161.828 Aktien zurück, was zu keiner Nettoveränderung gegenüber dem Bestand vor der Transaktion führt.

Die Meldung deutet auf eine routinemäßige Liquiditätsverwaltung des CEOs hin; es sind keine Auswirkungen auf die Unternehmensliquidität zu verzeichnen. Da die Transaktionen vorab geplant waren und das Gesamtbesitzniveau unverändert bleibt, ist die Marktauswirkung wahrscheinlich begrenzt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ALDRICH DAVID J

(Last) (First) (Middle)
C/O MOBIX LABS, INC.
1 VENTURE, SUITE 220

(Street)
IRVINE CA 92618

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MOBIX LABS, INC [ MOBX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/09/2025 A 226,677(1) D $0.00 242,889 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (Right to Buy) $4.18 (2) 08/10/2030 Class A Common Stock 20,000 20,000 D
Option (Right to Buy) $6.84 (2) 04/04/2032 Class A Common Stock 133,416 133,416 D
Explanation of Responses:
1. These Restricted Stock Units ("RSUs") were granted to the Reporting Person on July 9, 2025, whereas 90% of the award was fully vested upon grant and the remaining 10% will vest on October 1, 2025.
2. These options are fully vested and exercisable.
/s/ Terri Aprati, Attorney-in-Fact 07/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Disc Medicine (IRON) disclose in the July 11 2025 Form 4?

CEO John D. Quisel exercised 34,800 options at $9.86 and sold the same number of shares at ~$55�56 on 07/09/2025.

How many Disc Medicine shares does the CEO now own?

After the reported transactions, Quisel beneficially owns 161,828 common shares.

Were the insider sales pre-planned?

Yes. All transactions were executed under a Rule 10b5-1 trading plan adopted on February 13 2025.

What prices were the shares sold at?

Weighted-average prices were $55.2312 for 31,207 shares (range $55.00�$55.99) and $56.1995 for 3,593 shares (range $56.00�$56.33).

Did the CEO’s net ownership increase or decrease?

Neither. The exercise briefly increased holdings, but subsequent sales returned the stake to its prior level of 161,828 shares.
Mobix Labs Inc

NASDAQ:MOBX

MOBX Rankings

MOBX Latest News

MOBX Latest SEC Filings

MOBX Stock Data

42.70M
32.63M
31.53%
24.08%
3.14%
Semiconductors
Semiconductors & Related Devices
United States
IRVINE